Who
Robert Azelby
Director
Company insider
Files Form 4 as: Director, Autolus Therapeutics; Director, Tango Therapeutics; Director, ADC Therapeutics SA; Director, Terns Pharmaceuticals; Director, Cardinal Health; Director, Chinook Therapeutics; President & CEO, Climb Bio; Director, Clovis Oncology.
In numbers
- Trades disclosed
- 96
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $14.1M
- Companies
- 12
- Companies where not an officer
- 9
- First trade
- 1 Nov 2015
- Last trade
- 29 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,740 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,910 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,910 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,740 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $39K12,600 at $3.08 | filing |
| 3 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $39K12,600 at $3.08 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —90,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,697 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —90,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,697 | filing |
| 1 Feb 2026filed 2 Feb 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,697 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —1,697 at $0.00 | filing |
| 5 Nov 2025filed 6 Nov 2025 | CAH Cardinal HealthHealth Care Distribution | SEC FORM 4 Code A | —1,067 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $45K12,600 at $3.58 | filing |
News
Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) versus ADC Therapeutics (NYSE:ADCT)ADCT · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Robert Azelby; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.